IL-4 drives exhaustion of CD8+ CART cells

Carli M. Stewart(WinnMed), Saad S. Kenderian(Mayo Clinic in Arizona)

Nature Communications

September 12, 2024

10.1038/s41467-024-51978-3

Cited by 31

Related Papers

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

|Bone Marrow Transplantation|2019|119

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy

|Biology of Blood and Marrow Transplantation|2018|106

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

|Blood Advances|2024|19

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

|Blood|2022|12

Differential susceptibility and role for senescence in CART cells based on costimulatory domains

|Molecular Cancer|2025|3